文献速递胸部肿瘤

RET阳性非小细胞肺癌中治疗性膜靶点的表达

Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项多中心队列研究通过集中免疫组化和全转录组测序评估RET阳性非小细胞肺癌的膜靶点表达,发现MET和TROP2常见阳性,MET阳性率高于RET野生型腺癌对照,靶点共表达和动态变化提示需膜靶点筛查。

要点

  • RET阳性非小细胞肺癌中MET免疫组化阳性率为59%(51/86),TROP2为91%(59/65)。
  • 与RET野生型腺癌相比,RET阳性肿瘤MET阳性率更高(59% vs 43%,P=0.03),ERBB2更低(3.6% vs 15%,P=0.01)。
  • 61例可评估样本中97%(59/61)至少1个生物标志物阳性,排除TROP2后为78%(60/77)。

核心结论

  • RET阳性非小细胞肺癌肿瘤常表达MET和TROP2,且MET阳性率较RET野生型对照富集。
  • 靶点共表达和生物标志物动态变化提示需进行膜靶点筛查并探索新型治疗策略。

研究设计与样本

  • 多中心队列研究,对来自12个欧洲中心的存档组织样本进行集中免疫组化,并在独立队列中进行全转录组测序。
  • 免疫组化分析纳入RET阳性非小细胞肺癌和RET野生型腺癌对照样本;全转录组测序分析纳入203例RET阳性和19579例RET野生型样本。
  • 共纳入189例患者,其中RET阳性非小细胞肺癌81例,中位年龄62岁(IQR 55-70),女性49例(60%)。

主要发现

  • 在81例RET阳性非小细胞肺癌患者的93份样本中,免疫组化阳性率分别为MET 51/86(59%)、ERBB2 3/84(3.6%)、EGFR 24/84(29%)、HER3 31/82(38%)、TROP2 59/65(91%)。
  • 与RET野生型腺癌(n=112)相比,RET阳性肿瘤MET阳性率更高(59% vs 43%,P=0.03),ERBB2阳性率更低(3.6% vs 15%,P=0.01)。
  • 独立队列的全转录组测序分析证实了上述结果。
  • 61份可评估样本中,59份(97%)至少1个生物标志物阳性;排除TROP2后,77份中60份(78%)阳性。
  • MET/EGFR共表达见于79份可评估样本中的17份(21.5%);配对活检样本中观察到生物标志物表达动态变化。

关键数值与推荐

  • 免疫组化评分按0至3分,评分≥2分视为阳性。
  • 全转录组测序分析的靶点表达以每百万转录本中位数评分表示。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with advanced RET fusion-positive (RET+) non-small cell lung cancer (NSCLC) who experience disease progression following treatment with RET inhibitors (RETis) have limited treatment options. Identifying membrane protein targets may support the assessment of novel therapies, such as antibody-drug conjugates and bispecific antibodies. OBJECTIVE: To evaluate membrane target expression in RET+ NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study used centralized immunohistochemistry (IHC) on archival tissue samples and whole transcriptome sequencing (WTS) in an independent cohort. Tissue samples were collected from 12 European centers, and WTS was performed on globally sourced patient samples submitted for molecular profiling. This study included samples from patients with RET+ NSCLC and RET-wild-type (RET-wt) adenocarcinoma controls that were analyzed by IHC and 203 RET+ and 19 579 RET-wt samples analyzed by WTS. EXPOSURES: Membrane protein expression of MET, ERBB2 (formerly HER2), epidermal growth factor receptor (EGFR), human epidermal growth factor 3 (HER3), and trophoblastic cell surface antigen 2 (TROP2) was evaluated using IHC, with samples scored on a scale of 0 to 3. Scores of 2 or greater were considered positive. Target expression as analyzed by WTS was expressed as median transcript per million scores. MAIN OUTCOMES AND MEASURES: Biomarker positivity, coexpression of biomarkers, dynamic changes in paired biopsies, and clinical correlates with survival outcomes. RESULTS: A total of 189 patients were included in the study (among 81 patients with RET+ NSCLC, the median [IQR] age was 62 [55-70] years, and there were 49 female individuals [60%]). In 93 samples from 81 patients with RET+ NSCLC, positive IHC scores were observed for MET in 51 of 86 (59%), ERBB2 in 3 of 84 (3.6%), EGFR in 24 of 84 (29%), HER3 in 31 of 82 (38%), and TROP2 in 59 of 65 (91%). Compared with RET-wt adenocarcinoma (n = 112), RET+ tumors showed higher MET (59% vs 43%; P = .03) and lower ERBB2 expression (3.6% vs 15%; P = .01). The WTS analysis from the independent cohort confirmed these results. Of 61 evaluable samples, 59 of 61 (97%) had at least 1 positive biomarker, 60 of 77 (78%) when excluding TROP2. MET/EGFR coexpression occurred in 17 of 79 evaluable samples (21.5%). Dynamic change in biomarker expression was observed in paired biopsy specimens. No significant survival differences based on target expression emerged in patients treated with RETi in the IHC and the WTS cohorts. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that RET+ NSCLC tumors frequently express MET and TROP2, with MET positivity enriched vs RET-wt controls. Coexpression and biomarker dynamics highlight the need for membrane target screening and novel therapeutic strategies for this population.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Marinello A, Ghigna MR, Rotow JK, et al. Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer. JAMA Oncol. 2025. PMID: 40440007. doi:10.1001/jamaoncol.2025.1293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。